Literature DB >> 17852076

Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer.

Dejan Baskić1, Petar Ristić, Snezana Matić, Dragić Banković, Suzana Popović, Nebojsa Arsenijević.   

Abstract

OBJECTIVE: We investigated serum levels of CA 15-3, sHER2 and CA 125, and their usefulness in the detection of metastatic disease in breast cancer patients.
METHODS: The levels of CA 15-3, sHER2 and CA 125 tumour markers were determined in 60 patients, 40 with localized and 20 with metastatic breast carcinoma. The control group consisted of 10 healthy women.
RESULTS: We found that, at the time of diagnosis, serum levels of all three tumour markers were elevated in patients with distant metastases, but of minute importance in the detection of any breast cancer. When the data for the individual markers were combined the overall sensitivity of metastases detection with all three markers improved. In this regard, 90% of patients with distant metastases had an increase in serum level of at least one of tested tumour markers. Similar results were obtained using receiver operating characteristic curve (ROC). Moreover, using ROC we defined cut-off values for metastasis detection for each of the tested markers.
CONCLUSION: Our findings indicate that measurement of CA 15-3 serum values in conjunction with sHER2 and CA 15-3 can increase sensitivity in metastasis detection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17852076     DOI: 10.1080/13547500701520563

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  7 in total

Review 1.  Aberrant glycosylation as biomarker for cancer: focus on CD43.

Authors:  Franca Maria Tuccillo; Annamaria de Laurentiis; Camillo Palmieri; Giuseppe Fiume; Patrizia Bonelli; Antonella Borrelli; Pierfrancesco Tassone; Iris Scala; Franco Maria Buonaguro; Ileana Quinto; Giuseppe Scala
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

Review 2.  Current approaches and challenges in monitoring treatment responses in breast cancer.

Authors:  Lindsey J Graham; Matthew P Shupe; Erika J Schneble; Frederick L Flynt; Michael N Clemenshaw; Aaron D Kirkpatrick; Chris Gallagher; Aviram Nissan; Leonard Henry; Alexander Stojadinovic; George E Peoples; Nathan M Shumway
Journal:  J Cancer       Date:  2014-01-05       Impact factor: 4.207

3.  Diagnostic performance of circular RNAs in human cancers: A systematic review and meta-analysis.

Authors:  Juan Li; Hang Li; Xiaoting Lv; Zitai Yang; Min Gao; Yanhong Bi; Ziwei Zhang; Shengli Wang; Zhigang Cui; Baosen Zhou; Zhihua Yin
Journal:  Mol Genet Genomic Med       Date:  2019-05-20       Impact factor: 2.183

4.  Prognostic Models for Nonmetastatic Triple-Negative Breast Cancer Based on the Pretreatment Serum Tumor Markers with Machine Learning.

Authors:  Huihui Chen; Shijie Wu; Jun Hu; Kun Zhang; Kaimin Hu; Yuexin Lu; Jiapan He; Tao Pan; Yiding Chen
Journal:  J Oncol       Date:  2021-05-15       Impact factor: 4.375

5.  Serial Serum HER2 Measurements for the Detection of Breast Cancer Recurrence in HER2-Positive Patients.

Authors:  June-Hyung Ha; Min-Ki Seong; Eun-Kyu Kim; Jin Kyung Lee; Hyesil Seol; Ju Young Lee; Jangmoo Byeon; Yeun-Ju Sohn; Jae Soo Koh; In-Chul Park; Woo Chul Noh; Hyun-Ah Kim
Journal:  J Breast Cancer       Date:  2014-03-28       Impact factor: 3.588

6.  Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer.

Authors:  Wen-Zhao Chen; Jun-Feng Shen; Yang Zhou; Xuan-Yin Chen; Jia-Ming Liu; Zhi-Li Liu
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

7.  Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes.

Authors:  Cheng Fang; Yue Cao; Xiaoping Liu; Xian-Tao Zeng; Yirong Li
Journal:  Oncotarget       Date:  2017-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.